In the past, the names Baidu, Alibaba, Tencent, and ByteDance were synonymous with search engines, e-commerce, social media, and short-form videos. However, as we move through 2026, the center of gravity has shifted dramatically. The era of the "platform economy" is giving way to the era of "AI for Science" (AI4S). According to a recent analysis by 36Kr, China's internet giants are not just entering the field of AI Drug Discovery (AIDD); they are carving out radically different strategies that reflect each company's unique DNA.
Baidu: The Pioneer of Biological Foundation Models
Baidu was the first to seize the opportunity, as early as 2020. With its PaddleHelix platform, Robin Li's company did not stop at providing raw computing power. Instead, it focused on developing specialized models for protein folding and mRNA vaccine design. Baidu's strategy is "model-centric." Utilizing its PaddlePaddle deep learning framework, Baidu aims to create an ecosystem where pharmaceutical companies don't just buy software but rely on its foundation models to accelerate research. Their recent success in designing mRNA sequences that remain stable at room temperature represents a milestone for global biotechnology.
Tencent and Alibaba: Infrastructure vs. Clinical Optimization
Tencent, following a more "connective" approach, launched the iDrug platform. Its focus is less on pure biology and more on computational chemistry and the optimization of clinical trials. Tencent leverages its vast experience in managing user data to help pharma companies identify suitable candidates for trials, reducing costs that traditionally account for 60% of a drug's development budget. On the other hand, Alibaba, through its DAMO Academy, treats the problem as a cloud computing challenge. Its strategy focuses on providing the "backbone" for processing large-scale genomic data, working closely with hospitals and research centers to analyze medical imaging and diagnose rare diseases.
ByteDance: The Aggressive Newcomer
Perhaps the most intriguing case is that of ByteDance. Despite entering the sector later, the parent company of TikTok is moving with the same velocity that defined its social media dominance. ByteDance has engaged in aggressive recruitment of top-tier scientists from academia and the bioinformatics industry. Its approach is one of "interdisciplinary convergence." By combining Natural Language Processing (NLP)—where it excels—with structural biology, ByteDance attempts to "read" the genetic code as if it were text, searching for patterns that lead to new therapeutic targets. Their focus on cryo-electron microscopy and AI indicates an intent to dominate the early stages of discovery, where risks are high but rewards are monumental.
Challenges and the Future of AI4S
Despite the optimism, significant hurdles remain. Data silos in China, where hospitals are often reluctant to share information, represent the biggest obstacle. Furthermore, geopolitical tensions with the US limit access to advanced semiconductors (GPUs) essential for training these massive models. However, the trajectory is clear: Chinese giants no longer want to be mere trade intermediaries; they want to be the architects of the next generation of medicine. The transition from "clicks" to "cells" is perhaps the most significant pivot in the history of Chinese technology, promising an era where precision medicine becomes universally accessible.
